Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836

Archives

Author's Posts

WHAT ARE 6 HEALTH PROBLEMS THAT MIGHT BE TREATED BY STEM CELLS?

Stem cells are compleletly or partially undifferentiated or unprogrammed cells which are capable of developing into numerous types of cells and serving different functions in different parts of the body. The majority of cells in the human body are differentiated cells which means that they can serve only a specific purpose in a particular organ such as red blood cells that can only carry oxygen or carbon dioxide with the blood.

Stem cells can divide and make an indefinite number of copies of themselves. Stem cells can either remain stem cells or turn into differentiated cells such as red blood cells or muscle cells.

How stem cell could be useful for treating different diseases.

Scientists involved in stem cell research believe that stem cells can be useful for understanding mechanisms of diseases and treating those. Stem cells are being used to:

  • Replace damaged cells of organs or tissues,
  • Resore functions of tissues or organs that do not work properly,
  • Investigate mechanisms of genetic defect caused diseases,
  • Research how diseases develop or why certain cells become cancerous,
  • Test safety and effectiveness of new drugs.

The stem cell field has grown rapidly over the last two decades with stem cell treatments that include technologies to treat or prevent a disease condition. Stem cells have the potential to help treat numerous diseases by generating healthy new cells of almost all tissues.

Stem cell therapy for treating hematopoietic and genetic disorders

Stem cell therapy is being used to treat hematopoietic and genetic disorders. For instance in a cord blood transplant, stem cells are infused into a patient’s blood stream after which they help in healing and repairing of damaged tissues. Upon successful engraftment of the stem cells, the patient’s blood and immune systems are regenerated.

Six Health Problems that might be treated with stem cell therapy-

There are a wide range of diseases that are treatable with stem cells derived from cord blood or from other sources like bone marrow and peripheral blood. The diseases treatable by stem cells include acute and chronic forms of leukemia, myeloproliferative disorders, and many more.

The following six health problems might successfully be treated by stem cell therapy also known as regenerative medicine-

  • Leukaemia

Doctors are replacing cells damaged by chemotherapy or leukemia by performing stem cell transplant. Stem cell therapy is also serving as a way for supporting the patient’s immune system to fight some types of cancer and blood related diseases.

  • Diabetes – type 1

Embryonic stem cells when transplanted into people with type 1 diabetes is showing some very encouraging results towards the management of this disease.

  • Stroke

Stem cells are being used in clinical trials with evidence that when combined with clot busting or mechanical thrombectomy therapy enhances recovery. Stem cells injected into distant arteries or veins travel to the site of stroke in the brain fueling the repairing and recovery processes.

  • Kidney failure

Mesenchymal stem cells when administered independently are known to aid in kidney repair in cases of kidney failures.

  • Liver cirrhosis

The mechanism of mesenchymal stem cells or MSCs for treating liver cirrhosis /diseases has been evaluated from various perspectives. Adult stem cell therapies help induce the rapid production of hepatocytes in patients with liver cirrhosis.

  • Ulcerative colitis

Mesenchymal stem cells have displayed their immense potential for suppression of overactive immune response and for healing inflamed tissues. Therefore, these are emerging as a promising treatment of ulcerative colitis and inflammatory bowel disease or IBD, the diseases suspected to be rooted in localized inflammation in digestive tract.

The stem cell therapy has great potentials for treating and/or managing the six diseases mentioned above.

fa96881b-25e1-4d31-a04f-d1336ace8a26
GIOSTAR got the distinction of being named in the Insightscare.com Magazine as the “Company of the Month”. The Insightscare.com Magazine, which is one of the leading online healthcare magazines, published the journey of GIOSTAR becoming the world renowned institute of stem cell research and therapy.

The magazine also covered the interview given by Dr. Anand Srivastava – Chairman & Co-Founder of GIOSTAR for his expert opinion and future developments in the field of stem cell research and therapeutics.

The January-2021 edition of Insightscare.com also mentioned the able leadership of Mr. Deven Patel – CEO, President and Co-Founder of GIOSTAR who was honored with the USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the globe.

The magazine covered Dr. Anand Srivastava’s profound success and expertise in the field of stem cell biology, protein biochemistry, molecular biology, immunology, gene therapy and clinical research.

The magazine mentioned the big news of GIOSTAR FDA approval under compassionate use program and treatment of 53-year old critical COVID patient having recovered significantly after being infused with Stem Cells (MSCs).

Insightscares.com also reported how under the leadership of Mr. Deven Patel – GIOSTAR is heading the development of stem cell transplant program for four different state governments in India covering a population of approx. 155 million. The report further states that GIOSTAR in collaboration with the Gujarat government is building the world’s largest state-of-the-art stem cell treatment hospital in India.

The magazine also spelled out how GIOSTAR’s team members have been involved in the development and utilization of stem cell based clinical protocols related to malignant and non-malignant diseases for over two decades. Overall, GIOSTAR is named as a company that is poised to become the largest institute of excellence in the field of stem cell research and therapy on the earth.

Leading India towards an Immune Future

In August 2020, a 53-year-old COVID patient who was in a comatose state, struggling to hold on to life, was infused with Mesenchymal stem-cells taken from an umbilical cord. The results of this infusion were nothing less than enthralling as the patient recovered significantly in over three weeks.

This medical marvel was made possible by Global Institute of Stem Cell Therapy and Research (GIOSTAR), which is on a mission to administer the safest and most effective stem cell therapies and to deliver the highest quality care through its hospitals.

GIOSTAR was founded on the vision to provide stem cell-based therapy to people suffering from all kinds of degenerative or genetic diseases around the world. The company is evidently a leader in developing cutting edge stem cell-based technology, supported by leading scientists with pioneering publications in the area of stem cell biology. GIOSTAR was also one of the first company/research institute in the world which received USA-FDA approval in April 2020 to treat COVID-19 patients with stem cells.

The company’s primary focus is on discovering and developing a cure for human diseases through state-of-the-art and unique stem cell-based therapies and products. The company’s intellectual property, intellectual assets and technology have been developed over its team working on research projects funded to the tune of more than several hundred million dollars.

GIOSTAR is a coalition of esteemed and illustrious scientific minds in the field of genetic and stem cell science. The company’s team members have been involved in the development and utilization of stem cell based clinical protocols related to malignant and non-malignant diseases for the last 20 years.

The company’s leaders are associated with leading universities and research institutes of USA. GIOSTAR is affiliated with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute for Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA, Harvard Medical School, Imperial College, London.

“Our team has developed several research collaborations and has an extensive research experience in the stem cell therapy which is documented by several publications in revered scientific journals,” says Dr Anand Srivastava, the Chairman and Co-founder of GIOSTAR.

Dr Srivastava’s profound success has its root in his unique background and expertise in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research.

There are many scientists who can work in a narrowly defined field, but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as stem cell biology, cancer, and gene therapy. Dr Srivastava’s wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR’s projects for stem cell transplant, cancer, and gene therapy research. Dr Srivastava is also serving as stem cell director for the government of Gujarat, India and is in the process of establishing the stem cell program for Gujarat, Government of India.

The team at GIOSTAR is reaching heights of success also under the able leadership of Mr. Deven Patel, the CEOPresident and Cofounder. Mr. Patel was honoured with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world. He was also bestowed with the Asian Heritage Award for his business leadership in the field of stem cell science.

GIOSTAR, under the leadership of Mr. Patel, is heading the development of stem cell transplant program for four different State Governments in India with total population of approx. 155 million. The company, in collaborations with Government of Gujarat, India, has founded the world’s largest state-of-the-art stem cell treatment hospital in India. GIOSTAR is also in process of developing additional facilities in China, Thailand, Colombia, Bahamas, Dubai, and Australia.

Talking about how GIOSTAR successfully found the solution to treat COVID-19 related health issues, Dr Srivastava explains, “COVID-19 infection leads to uncontrolled release of proinflammatory cytokines known as ‘cytokine storms’ that potentially lead to fatal damage of many organs of the body. MSCs have specific characteristics that, when infused in the bloodstream, neutralize proinflammatory cytokines (through ‘immunomodulation’), down-regulate the inflammatory gene actions and send messages to regenerate damaged lung and other tissues, which may help in managing COVID-19.” GIOSTAR is also gearing up to start its clinical trial for patients with aftereffects of COVID-19 on lungs and other organs.

We asked Dr Srivastava about his opinion on the necessity for businesses to align their offerings with newer technological developments, especially when it comes to changing industry trends and customer preferences, to which he replied, “Scientific research is an ever-evolving process. GIOSTAR being hard core research organization allows it to be at the forefront of new innovations and possible cure for several incurable disease. This same mindset has made us one of the first research institutes in the world to get very early approval form USA-FDA to treat COVID-19 patients with stem cells.”

Mr. Patel on the other hand shared a few tokens of knowledge through the commercial perspective of regenerative medicine development, he says, “The pharma and scientific research businesses are very competitive, at very high level of science and at very high cost. Therefore, a simple advice to aspiring entrepreneurs is to first get their ducks in the row and get your finances figured out way in advance, otherwise it is very easy to bankrupt the company in this volatile economy.”

GIOSTAR’s plan to continue scaling its operation, keeping in mind the unpredictable future, can be viewed to be agile and ready to run. Pertaining to stable finances, the company’s pipeline of several technologies is very robust and in line with its projections. GIOSTAR is poised to be the largest stem cell research and therapy company on the earth. The company is already becoming a synonym for the stem cell treatment.

Read More : https://insightscare.com/giostar-leading-india-towards-an-immune-future/

WhatsApp Image 2021-01-06 at 10.28.10 AM

Civic Youth Conclave is a two-day virtual deliberation to be held on 9th and 10th January 2021. It is modeled on United Nations Conference with participants from all across the world. The Secretariat has envisioned this conference to be a platform to provide exposure to students and a safe space for them to put forth their cogent opinions. We are striving to make a difference and empower the youth for they are the future generation. We believe that MUN can lead to a deeper understanding of real-world problems and hence, lead to the youth finding solutions towards absolute world peace.

 

Experimental COVID treatment may have saved man’s life

 

Experimental COVID treatment may have saved man's life

Video Link : https://www.10news.com/news/coronavirus/experimental-covid-treatment-may-have-saved-mans-life

 

SAN DIEGO — A San Diego-based stem cell research institute believes its discovery may have saved the life of a COVID patient on death’s doorstep.

GIOSTAR infused a 53-year-old man in a coma with Mesenchymal stem-cells taken from an umbilical cord. Prior to that, all other treatments were failing.

“He was having a stroke, he was under dialysis, liver function was declining,” said Dr. Anand Srivastava, co-founder of GIOSTAR. “Nothing was working.”

The patient, whose identity is not being released due to privacy laws, had been in a coma in a New Jersey hospital. GIOSTAR got special clearance from the Food and Drug Administration to try the stem-cell treatment.

Srivastava said the patient began to recover, gradually over three weeks.

“Slowly, his renal and liver function came closer to normal,” he said. “He came out from the intubation, and now he is talking.”

The family, in an interview with GIOSTAR, said they had lost all hope.

Srivastava said this treatment could be key as society awaits a vaccine.

GIOSTAR is planning to do a double-blind study to confirm its conclusions about its treatment. It says that study should take about three months.

Source : https://www.10news.com/news/coronavirus/experimental-covid-treatment-may-have-saved-mans-life

Mesenchymal Stem Cells May Be A Credible Alternative Therapy To Fight With COVID-19 Pandemic

 

Coronavirus disease 2019 (COVID-19), a highly contagious disease, is propelled by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First identified in December 2019 in Wuhan quickly forced the World Health Organization (WHO) to declare the 2019–20 coronavirus outbreak a Public Health Emergency of International Concern (PHEIC)on 29 January 2020 and a pandemic on 11 March 2020.1-3 Following the emergence global powers are scrambling in search of reliable treatments urgently, and vaccines for future use. The deathly pathogenic virus has caused more than 3 million cases and two thousand deaths worldwide by April 29th, inciting the fear that the numbers may continue to increase. Common symptoms of COVID-19 include, but are not limited to, fever, cough, fatigue, shortness of breath, and loss of smell sense. Severe additional symptoms included in the list but not limited to are difficulty in breathing, persistent chest pain, confusion, and difficulty in waking up.While many cases only display mild symptoms, others may manifest a form of viral pneumonia leading to multi-organ failure and could be fatal.4-6 The viral infection causes a vicious release of different proinflammatory cytokines or a cytokine storm thought to be the root cause of organ failures.5 The virus has been recorded to spread between humans following a close contact with someone who has been infected,via small droplets that come from coughing or sneezing.Many humans can also get infected by being even in the vicinity of an infected person or after coming in contact of a contaminated surface and thentouching their face. The standard method of diagnosis and testing used by many countries is the method of real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Chest CT imaging isalso helpfulduring the diagnosis stage; however, CDC guidelines do not recommend chest scans for routine screening.

COVID-19 affects the lungs the most, because the virus attacks host cells via the angiotensin-converting enzyme 2 receptor (ACE2). ACE2 is found on the surface of different cell types but type II alveolar cells present in the lungs are very rich in its content. The virus has a surface glycoprotein called a “spike” (peplomer) which helps in accessing the ACE2 and invade the host cell. Therefore, density of ACE2 in the cells of a tissue is related to with the severity of the effect of the infection. Considering its role in infection, many scientists have hypothesized that decreasing ACE2 activity might have positive effects in inhibiting infection. Though an opposing view also exists according to which increasing ACE2 activity by using angiotensin II receptor blocker may be protective.Both of these ideas need to be rigorously tested before either of these could be a guiding force for developing a therapeutic intervention. When the alveolar disease begins to progress, respiratory failure may begin and death may result. The virus also attacks gastrointestinal organs as ACE2 is present.

Currently, there is no available vaccine or specific antiviral treatment for COVID-19. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures. Because of the emergent need, medical professionals have rushed

Approval of MSCs for therapeutic is gaining acceptance around the globe.In Japan, MSCs have been approved for the treatment of another clinical condition called graft-versus-host disease.There are other such pending approvals in the US also as a number of clinical trials starting to test the benefits of MSCs for treating COVID-19 are at different stages.Many scientists, on the basis of the immune- modulatory ability of MSCs and other circumstantial evidence, think that MSCs should alleviate the symptoms in COVID-19 patients. It was evident by the Chinese study, which was reported in “Aging and Disease” last month also.The findings based on seven COVID-19 patients who received intravenous infusions of MSCs recovered successfully and were discharged from the hospital by the end of the 14-day observation period. In contrast, of the three patients of the control group receiving regular treatment, all of whom had severe disease, one died, one developed ARDS, and one achieved a stable condition.7,8

Many scientists see that MSCs could be a very promising approach for treatment of COVID-19 patients though the findings are based on a small number of subjects.Other scientists also think that the report demonstrates that the MSCs are not only well received by the patients but also impart a great therapeutic relief. Following the recent approval by FDA of the treatment for extreme cases and trials together with the recruitment of COVID-19 patients to existing MSC trials for ARDS around the world a significant amount of data will demonstrate the therapeutic value of allogenic stem cell-based treatments in COVID-19 patients. Reviewing all the developing data, we suggest that clinicians may safely use MSCs to manage those patients who are in severe condition. MSCs may also be used as a credible preventive therapy to make the immune system ready to fight the virus in case of any possible COVID-19 infection.

Prabhat Soni, Anand Srivastava
Global Institute of Stem Cell Therapy and Research (GIOSTAR),
USA

Correspondence: Anand Srivastava,

Global Institute of Stem Cell Therapy and Research (GIOSTAR),

4660 La Jolla Village Drive, San Diego, CA, 92122, USA,

Email: anand@giostar.com

Received: May 01, 2020 | Published: June 11, 2020

References

1. Symptoms of Coronavirus. U.S. Centers for Disease Control and Prevention (CDC).
2. Q&A on coronaviruses (COVID-19). World Health Organization (WHO).
3. Hopkins, Claire. Loss of sense of smell as marker of COVID-19 infection. Ear, Nose and Throat surgery body of United Kingdom.
4. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
5. Puja Mehta, Daniel F McAuley, Michael Brown, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034.
6. “Q&A on coronaviruses”. World Health Organization (WHO).
7. Gu Jinyang, Han Bing, Wang Jian. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission”. Gastroenterology.
8. Leng Zikuan, Zhu Rongjia, Hou Wei, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and disease. 2020;11(2):216–228.

Mesenchymal stem cells may be a credible alternative therapy to fight with COVID-19 pandemic

Make An Inquiry

We are here to help you

WordPress Video Lightbox